AbCellera Biologics Analyst Ratings
AbCellera Biologics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/31/2023 | 106.9% | Benchmark | $20 → $12 | Maintains | Buy |
| 08/04/2023 | 313.79% | Goldman Sachs | $27 → $24 | Maintains | Buy |
| 05/05/2023 | 382.76% | Credit Suisse | $34 → $28 | Maintains | Outperform |
| 02/28/2023 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 02/22/2023 | 451.72% | BMO Capital | $40 → $32 | Maintains | Outperform |
| 02/22/2023 | 486.21% | Credit Suisse | → $34 | Reiterates | → Outperform |
| 01/06/2023 | 210.34% | SVB Leerink | $20 → $18 | Maintains | Outperform |
| 12/15/2022 | 417.24% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 11/16/2022 | 400% | Truist Securities | → $29 | Initiates Coverage On | → Buy |
| 11/09/2022 | 244.83% | SVB Leerink | $13 → $20 | Maintains | Outperform |
| 08/10/2022 | 486.21% | Credit Suisse | $40 → $34 | Maintains | Outperform |
| 07/26/2022 | 279.31% | Piper Sandler | $21 → $22 | Maintains | Overweight |
| 05/11/2022 | 262.07% | Piper Sandler | $28 → $21 | Maintains | Overweight |
| 05/11/2022 | 141.38% | SVB Leerink | $20 → $14 | Maintains | Outperform |
| 02/25/2022 | 589.66% | Credit Suisse | $39 → $40 | Maintains | Outperform |
| 02/25/2022 | 244.83% | SVB Leerink | $25 → $20 | Maintains | Outperform |
| 12/21/2021 | 365.52% | Benchmark | → $27 | Initiates Coverage On | → Buy |
| 11/19/2021 | 468.97% | Piper Sandler | → $33 | Initiates Coverage On | → Overweight |
| 08/13/2021 | 744.83% | Credit Suisse | $51 → $49 | Maintains | Outperform |
| 05/14/2021 | 779.31% | Credit Suisse | $53 → $51 | Maintains | Outperform |
| 03/30/2021 | 848.28% | Stifel | $59 → $55 | Maintains | Buy |
| 02/08/2021 | 796.55% | SVB Leerink | $45 → $52 | Maintains | Outperform |
| 01/05/2021 | 813.79% | Berenberg | → $53 | Initiates Coverage On | → Buy |
| 01/05/2021 | 675.86% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 01/05/2021 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 01/05/2021 | 917.24% | Stifel | → $59 | Initiates Coverage On | → Buy |
| 01/05/2021 | 727.59% | BMO Capital | → $48 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/31/2023 | 106.9% | 基準 | 20 美元 → 12 美元 | 維護 | 購買 |
| 08/04/2023 | 313.79% | 高盛 | 27 美元 → 24 美元 | 維護 | 購買 |
| 05/05/2023 | 382.76% | 瑞士信貸 | 34 美元 → 28 美元 | 維護 | 跑贏大盤 |
| 02/28/2023 | — | Cowen & Co. | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 02/22/2023 | 451.72% | BMO Capital | 40 美元 → 32 美元 | 維護 | 跑贏大盤 |
| 02/22/2023 | 486.21% | 瑞士信貸 | → 34 美元 | 重申 | → 跑贏大盤 |
| 01/06/2023 | 210.34% | SVB Leerink | 20 美元 → 18 美元 | 維護 | 跑贏大盤 |
| 2022 年 12 月 15 日 | 417.24% | 高盛 | → 30 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/16/2022 | 400% | 信託證券 | → 29 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/09/2022 | 244.83% | SVB Leerink | 13 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 08/10/2022 | 486.21% | 瑞士信貸 | 40 美元 → 34 美元 | 維護 | 跑贏大盤 |
| 07/26/2022 | 279.31% | 派珀·桑德勒 | 21 美元 → 22 美元 | 維護 | 超重 |
| 05/11/2022 | 262.07% | 派珀·桑德勒 | 28 美元 → 21 美元 | 維護 | 超重 |
| 05/11/2022 | 141.38% | SVB Leerink | 20 美元 → 14 美元 | 維護 | 跑贏大盤 |
| 2022 年 2 月 25 日 | 589.66% | 瑞士信貸 | 39 美元 → 40 美元 | 維護 | 跑贏大盤 |
| 2022 年 2 月 25 日 | 244.83% | SVB Leerink | 25 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 2021 年 12 月 21 日 | 365.52% | 基準 | → 27 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/19/2021 | 468.97% | 派珀·桑德勒 | → 33 美元 | 啓動覆蓋開啓 | → 超重 |
| 08/13/2021 | 744.83% | 瑞士信貸 | 51 美元 → 49 美元 | 維護 | 跑贏大盤 |
| 05/14/2021 | 779.31% | 瑞士信貸 | 53 美元 → 51 美元 | 維護 | 跑贏大盤 |
| 03/30/2021 | 848.28% | Stifel | 59 美元 → 55 美元 | 維護 | 購買 |
| 02/08/2021 | 796.55% | SVB Leerink | 45 美元 → 52 美元 | 維護 | 跑贏大盤 |
| 01/05/2021 | 813.79% | 貝倫貝格 | → 53 美元 | 啓動覆蓋開啓 | → 購買 |
| 01/05/2021 | 675.86% | SVB Leerink | → 45 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 01/05/2021 | — | 瑞士信貸 | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 01/05/2021 | 917.24% | Stifel | → 59 美元 | 啓動覆蓋開啓 | → 購買 |
| 01/05/2021 | 727.59% | BMO Capital | → 48 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
What is the target price for AbCellera Biologics (ABCL)?
Abcellera Biologics（ABCL）的目標價格是多少？
The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 106.90% upside). 10 analyst firms have reported ratings in the last year.
Benchmark於2023年8月31日公佈了Abcellera Biologics（納斯達克股票代碼：ABCL）的最新目標股價。該分析公司將目標股價定爲12.00美元，預計ABCL將在12個月內上漲至106.90％（可能上漲106.90％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for AbCellera Biologics (ABCL)?
分析師對abCellera Biologics（ABCL）的最新評級是多少？
The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.
Benchmark提供了Abcellera Biologics（納斯達克股票代碼：ABCL）的最新分析師評級，Abcellera Biologics維持買入評級。
When is the next analyst rating going to be posted or updated for AbCellera Biologics (ABCL)?
Abcellera Biologics（ABCL）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Abcellera Biologics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Abcellera Biologics的最新評級是在2023年8月31日提交的，因此你應該預計下一個評級將在2024年8月31日左右公佈。
Is the Analyst Rating AbCellera Biologics (ABCL) correct?
分析師對 abCellera Biologics (ABCL) 的評級正確嗎？
While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $5.80, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Abcellera Biologics（ABCL）評級保持不變，目標股價爲20.00美元至12.00美元。Abcellera Biologics（ABCL）目前的交易價格爲5.80美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。